Last reviewed · How we verify
Fruquintinib and Everolimus — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Fruquintinib and Everolimus (Fruquintinib and Everolimus) — Peking University First Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fruquintinib and Everolimus TARGET | Fruquintinib and Everolimus | Peking University First Hospital | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fruquintinib and Everolimus CI watch — RSS
- Fruquintinib and Everolimus CI watch — Atom
- Fruquintinib and Everolimus CI watch — JSON
- Fruquintinib and Everolimus alone — RSS
Cite this brief
Drug Landscape (2026). Fruquintinib and Everolimus — Competitive Intelligence Brief. https://druglandscape.com/ci/fruquintinib-and-everolimus. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab